

# PharmaFORUM Webcast Biologics

Development, Quality and Regulatory Affairs

---

## The upcoming webcasts at a glance

- Early and late-stage biotherapeutic development
- Quality documentation for biotech IMPs
- Cell line development and virus safety
- Upstream and downstream development
- Formulation, analytics and bioassay setups
- Stability concept – pre and post launch
- Comparability – similarity assessment
- ICH Q12: CMC lifecycle management

Please try us out:  
A free demo is  
online available!

---

## Your benefits

- One live webcast with international experts every month
- Consolidated information in a short period of time at your work place
- Possibility to directly interact with the speaker via chat

## Concept

Do you work with biologics? Then, we would like to invite you to join our live webcast series.

Our experts will provide you with the latest information on the current challenges in analytics, development, quality and regulatory affairs (pre- and post-authorisation phases) of biologics every month. Most webcasts are specifically focused on CMC while addressing topics at the interface quality and regulatory affairs.

You will meet our experts in a virtual conference room and share your experiences live. Each meeting will be held as a 1.5 to 2-hour webcast, presenting the latest news with supporting presentation slides. To be best prepared, you will be able to download the complete presentation documents prior to each webcast.

## Your benefits

- Twelve live webcasts with international experts per year.
- Recorded webcasts at our learning centre to review as often as you like.
- Documentation for your download.
- Multiple choice test after each webcast to obtain a personal certificate.

## Additional useful information

Are you unable to attend one of the webcasts? No problem! Following each live meeting, you will be able to retrieve the recorded webcast from our learning centre using your personal password. This allows you to review each webcast at any time and as often as you like. An optional multiple choice test finalizes each webcast, giving you the possibility to receive a personal certificate.

Get a first impression at [www.forum-institut.com/pharma-webcast-biologics](http://www.forum-institut.com/pharma-webcast-biologics)

## Technical requirements

In order to join in our live webcast, you will need a standard PC with a current browser, a soundcard, speakers or a headset, and a reliable Internet connection. You may choose between calling via telephone and calling via computer (VoIP) for audio connectivity.

Your Programme	Date	Your Expert
<b>Interaction with Agencies</b> <ul style="list-style-type: none"> <li>■ National “versus” EMA Scientific Advice</li> <li>■ Strategically plan interaction with authorities</li> <li>■ What to expect from the interaction</li> </ul>	26 October 2018	Dr Christian Schneider
<b>QbD elements in early and late stage biotherapeutic development (from research to first in human until commercial)</b> Implementation of QbD elements: <ul style="list-style-type: none"> <li>■ Quality attributes/critical quality attributes</li> <li>■ quality target product profile (QTPP)</li> <li>■ Comparability studies</li> </ul>	27 November 2018	Dr Dorothee Ambrosius
<b>Quality of biotech IMPs – the current challenges</b> <ul style="list-style-type: none"> <li>■ Impact of the current voluntary harmonisation procedure (VHP) and the new clinical trial regulation on pharmaceutical quality</li> <li>■ Current and future regulatory scientific requirements and challenges with regards to quality and its documentation</li> </ul>	11 December 2018	Dr Jörg Engelbergs
<b>Analytical development concepts to guide CMC development</b> <ul style="list-style-type: none"> <li>■ Current analytical methods</li> <li>■ Specification and validation</li> <li>■ Developmental vs. CMC data</li> </ul>	22 January 2019	Dr René Thürmer -requested-
<b>Cell line development</b> <ul style="list-style-type: none"> <li>■ Host cells</li> <li>■ State-of-the-art cell line generation process</li> <li>■ Importance of monoclonality assurance</li> <li>■ Bioreactor assessment, clone characterization, expression vector design</li> <li>■ Phenotypic &amp; genotypic stability</li> </ul>	13 February 2019	Dr Barbara Enenkel and Dr Simon Fischer
<b>Virus safety</b> <ul style="list-style-type: none"> <li>■ Potential sources of virus contamination</li> <li>■ Cell line qualification: testing for viruses</li> <li>■ Testing for viruses in unprocessed bulk</li> <li>■ Virus validation studies</li> </ul>	13 March 2019	Dr Barbara Enenkel and Dr Sabine Häcker

Your Programme	Date	Your Expert
<b>Upstream development (early and late stage)</b> <ul style="list-style-type: none"> <li>■ Process characterisation</li> <li>■ Fermentation development</li> <li>■ Scale-up and scale-down approaches</li> </ul>	9 April 2019	Dr Markus M. Müller
<b>Downstream development (late stage)</b> <ul style="list-style-type: none"> <li>■ Late stage development</li> <li>■ Stage I validation</li> </ul>	14 May 2019	Jessica Stolzenberger
<b>Pharmaceutical development of biologics drug products: the interface of formulation, primary packaging and application</b>	4 June 2019	Dr Susanne Jörg
<b>Bioassays</b> <ul style="list-style-type: none"> <li>■ Why are they needed?</li> <li>■ Advantages/disadvantages of bioassay setups</li> <li>■ Replacement of bioassays</li> </ul>	2 July 2019	Dr Katrin Buss -requested-
<b>Stability concept: pre- and post-launch</b> <ul style="list-style-type: none"> <li>■ Stability programmes</li> <li>■ Use of bracketing/matrixing</li> <li>■ Extrapolation of the shelf life</li> <li>■ Stress stability studies</li> <li>■ Stability indicating methods</li> <li>■ Container closure integrity testing</li> </ul>	August 2019 (date will be announced)	Dr Rainer Ilg
<b>Comparability – similarity assessment</b> <ul style="list-style-type: none"> <li>■ Differences and common features                             <ul style="list-style-type: none"> <li>■ Assessment of critical quality attributes</li> </ul> </li> <li>■ Demonstration of analytical comparability</li> <li>■ Demonstration of analytical similarity                             <ul style="list-style-type: none"> <li>■ Different approaches to show similarity in US and EU</li> <li>■ Justification of differences</li> </ul> </li> </ul>	17 September 2019	Dr Beatrix Metzner and Dr Manuel Wittner
<b>CMC lifecycle management: ICH Q12 and others</b> <ul style="list-style-type: none"> <li>■ Post-approval change management protocol (PCMP)</li> <li>■ How to achieve regulatory flexibility?</li> <li>■ Requirements regarding tech transfer</li> </ul>	15 October 2019	Dr Steffen Groß

## Your experts



**Dr Dorothee Ambrosius**  
Boehringer Ingelheim  
Pharma GmbH & Co. KG  
Head of CMC Strategy  
Biologicals



**Dr Susanne Jörg**  
Lonza AG, Switzerland  
Head of Formulation  
Development



**Dr Katrin Buss**  
-requested-  
Expert for pharmaceutical  
Quality and Regulatory  
Affairs, Bonn, Germany



**Dr Beatrix Metzner**  
Boehringer Ingelheim  
Pharma GmbH & Co. KG  
Head of Global Tech RA

### Dr Barbara Enenkel

Boehringer Ingelheim Pharma GmbH & Co. KG  
Senior Associate Director Bioprocess and  
Analytical Development



**Dr Markus M. Müller**  
Boehringer Ingelheim  
Pharma GmbH & Co. KG  
Associate Director of Cell  
Culture Development CMB



**Dr Jörg Engelbergs**  
Paul-Ehrlich-Institut (PEI),  
Langen, Germany



**Dr Christian Schneider**  
National Institute for  
Biological Standards and  
Control (NIBSC),  
United Kingdom  
Director



**Dr Simon Fischer**  
Boehringer Ingelheim  
Pharma GmbH & Co. KG  
Head of Cell Line Develop-  
ment CMB



**Jessica Stolzenberger**  
Boehringer Ingelheim  
Pharma GmbH & Co. KG  
Head of Laboratory, Late  
Stage DSP Development



**Dr Steffen Groß**  
Paul-Ehrlich-Institut (PEI),  
Langen, Germany



**Dr René Thürmer**  
-requested-  
Expert for pharmaceutical  
Quality, Bonn, Germany



**Dr Sabine Häcker**  
Boehringer Ingelheim  
Pharma GmbH & Co. KG  
Head Virus Test



**Dr Rainer Ilg**  
Boehringer Ingelheim  
Pharma GmbH & Co. KG  
Senior Associate Director,  
Global Technical Regulatory  
Affairs



**Dr Manuel Wittner**  
Boehringer Ingelheim  
Pharma GmbH & Co. KG  
Associate Director, Global  
Technical Regulatory Affairs

Registration under  
service@forum-institut.com or  
Fax +49 6221 500-555

## Registration Form

Yes, I want to join the

- PharmaFORUM Webcast Biologics**  
(you will receive a confirmation email  
with your login details)

- Yes, i agree that FORUM Institut may inform me about  
events and relevant expert content by:  
 email; and/or  telephone.  
I may withdraw my consent at any time.

Name \_\_\_\_\_

Position/Department \_\_\_\_\_

Company \_\_\_\_\_

Street \_\_\_\_\_

Postal Code/City/Country \_\_\_\_\_

Tel. No. \_\_\_\_\_

E-Mail \_\_\_\_\_

Contact person at office \_\_\_\_\_

Date, Signature \_\_\_\_\_

## How to register

- **Registration: +49 6221 500-500**
- **Conference-No. 19 10 279**

### ■ **Fee:**

Membership of the PharmaFORUM Webcast Biologics  
is available for one year.

**The annual membership fee of €1,800**

(plus German VAT) for twelve webcasts is due upon  
registration.

Membership is automatically extended by one year,  
unless written notice has been submitted no later  
than six weeks before the end of the membership.

A 12-month membership may be started at any time.

If you are interested in a group account, please  
contact us.

### **Benefits:**

- Twelve live webcasts per year
- Recorded presentations available at our  
learning centre
- Documentations for your personal download
- Multiple choice test and personal certificate  
after each webcast

## Questions and information:



I am gladly at your disposal should  
you have any further questions  
about the Webcast series.

**Laura Vogelmann**  
Conference Manager  
Pharmaceuticals & Healthcare  
Tel. +49 6221 500-655  
l.vogelmann@forum-institut.de

## Cancellation Policy

Our general terms and conditions apply (as of 01.01.2016)  
and are available upon request.

We can send them to you anytime or you can find them  
online at [www.forum-institut.com/t&c](http://www.forum-institut.com/t&c).

Please look at the special terms and conditions for online  
offers.